BMS
SLNO

Brummer Multi-Strategy’s Soleno Therapeutics SLNO Stock Holding History

Brummer Multi-Strategy’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,741
Closed -$405K – 14
2025
Q4 		$405K Buy
+8,741
New +$479K 2.45% 9

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Brummer Multi-Strategy's SLNO Position: Q1 2026 in Review

Brummer Multi-Strategy sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 8,741 shares — an estimated $405K sold.

Brummer Multi-Strategy first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $405K in Q4 2025. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Brummer Multi-Strategy reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brummer Multi-Strategy sold 8,741 Soleno Therapeutics shares in Q1 2026, an estimated $405K.
  • Brummer Multi-Strategy first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
  • Brummer Multi-Strategy's Soleno Therapeutics position peaked at $405K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Brummer Multi-Strategy's 13F filing for Q1 2026, filed 6 May 2026.